Citius Pharmaceuticals, Inc. (NASDAQ: CTXR) is transitioning from a development-stage biotech to a commercial-stage company, underscored by the FDA approval and subsequent launch of LYMPHIR™ (denileukin diftitox-cxdl) for relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL). The drug generated $5.6 million in net revenue in the first six months of fiscal 2026, with approximately 80% gross margins, following its December 2025 commercial launch. This milestone not only provides a revenue stream but also validates the company's strategy of targeting critical-care indications with significant unmet needs.
The commercial progress of LYMPHIR™ is complemented by a robust pipeline. Mino-Lok®, an antibiotic lock solution for catheter-related bloodstream infections, met primary and secondary endpoints in its pivotal Phase 3 trial. With no FDA-approved therapies specifically indicated to salvage infected central venous catheters, Mino-Lok® addresses a serious complication in cancer and hemodialysis patients. The company has received QIDP and Fast Track designations and is working with the FDA on a pathway to a New Drug Application. Investor materials estimate worldwide sales potential of approximately $1.8 billion.
Another promising candidate is Halo-Lido (CITI-002), a topical formulation combining halobetasol and lidocaine for the symptomatic treatment of hemorrhoids. With an estimated 10 million Americans reporting symptoms annually and no FDA-approved prescription product for this condition, Halo-Lido could become the first such treatment if approved. The company completed a Phase 2b study and has engaged with the FDA on next steps.
Additionally, Citius is developing a stem cell platform using induced pluripotent stem cell-derived mesenchymal stem cells (i-MSCs) for acute respiratory distress syndrome (ARDS), including sepsis-induced lung injury. Proof-of-concept studies in sheep showed improvements in oxygenation and other measures, supporting further development.
The company's leadership, including CEO Leonard Mazur and Executive Vice Chairman Myron Holubiak, brings decades of pharmaceutical experience. This expertise is crucial as Citius navigates commercialization and regulatory processes. With LYMPHIR™ now commercial and multiple pipeline catalysts, Citius is positioned for potential growth. The company also reports nearly 100% payer coverage for LYMPHIR™ and has begun expanding into Europe, with an initial shipment in April 2026.
Investor interest is heightened by these developments, as Citius continues to execute on its strategy of advancing differentiated therapies. The combination of a revenue-generating product and late-stage pipeline assets offers multiple pathways for value creation. As the company progresses, it remains focused on addressing critical-care needs, potentially reshaping treatment paradigms in oncology and infectious disease.
